A Next Generation Stem Cell Therapeutics Company

Dr Ross Macdonald, CEO
Cynata Therapeutics Limited
AusBiotech Asia Investment Series, March 2019
This presentation has been prepared by Cynata Therapeutics Limited. ("Cynata" or the "Company") based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Cynata, nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Cynata Therapeutics and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Cynata Therapeutics is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Cynata Therapeutics securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Cynata Therapeutics, its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Cynata Therapeutics does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

The distribution of this presentation may be restricted by law and you should observe any such restrictions.

Forward looking statements

This presentation contains certain forward looking statements that are based on the Company’s management’s beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Cynata to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the political and economic environment in which Cynata will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Cynata and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).
Cynata Therapeutics is a Phase II-ready biotech with a highly scalable, proprietary platform for developing cellular therapeutics

About Cynata Therapeutics

- Australian stock exchange (ASX) listed
- Regenerative medicine company with a platform technology to produce cellular therapeutics at scale
- Proprietary Cymerus™ platform technology harnesses the proven unlimited expansion potential of induced pluripotent stem cells (iPSCs)
- Patented process of converting iPSCs into mesenchymal stem cells (MSCs), developed at the University of Wisconsin-Madison (a global leader in stem cell research)
- Attractive licensing business model
- Globally experienced Board and management team

Top shareholders

<table>
<thead>
<tr>
<th>Shareholder</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fidelity</td>
<td>9.3%</td>
</tr>
<tr>
<td>FUJIFILM</td>
<td>7.9%</td>
</tr>
<tr>
<td>Board and management</td>
<td>6.2%</td>
</tr>
</tbody>
</table>

Financial information

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Share price (22-Mar-19)</td>
<td>A$1.18</td>
</tr>
<tr>
<td>Shares on issue</td>
<td>101.8m</td>
</tr>
<tr>
<td>Market capitalisation</td>
<td>A$120.2m</td>
</tr>
<tr>
<td>Cash¹</td>
<td>A$11.5m</td>
</tr>
<tr>
<td>Debt</td>
<td>-</td>
</tr>
<tr>
<td>Enterprise value</td>
<td>A$108.6m</td>
</tr>
<tr>
<td></td>
<td>~US$76.9m</td>
</tr>
</tbody>
</table>

Share price performance (A$)

Source: IRESS

1. Cash balance as at 31-Dec-18 of A$10.6m, adjusted for an additional A$0.9m received from the exercise of options since 31 Dec 2018 (as at 22-Mar-19)
Cynata has the only platform in the world to produce commercial quantities of MSCs from a single source.

**iPSCs**
- Mature cells (e.g. blood donation)
- Induced Pluripotent Stem Cells (iPSCs)

**Cymerus™ technology platform**
- Expansion of iPSCs
- Precursor cells
- Precursor cell colonies (mesenchymo-angioblasts)
- Differentiation into MSCs & packaging

**MSCs**
- Cellular therapies administered to patient

---

**Key advantages of the Cymerus process:**
- ✓ SCALABILITY & CONSISTENCY
- ✓ FEWER CELLS PER PATIENT
**GvHD clinical trial** | Highly successful outcome, with majority of patients reporting a Complete Response from a devastating disease

---

**Phase I clinical trial data – all endpoints achieved**

- **53%** Complete Response rate
- **87%** Overall Response rate
- ≥**87%** Overall survival rate

---

**Individual patient data**

![Graph showing individual patient data](image)

---

**Legend**

- **GvHD grade**
  - GvHD grade: As at day 0
  - GvHD grade: Best Response

- **Patient response**
  - C: Complete Response
  - P: Partial Response
  - S: Stable disease

---

1. Pooled Cohort A/B results at 100 days.
2. Absence of GvHD.
3. Overall Response is either a Complete or Partial Response (improvement by 1+ grade).
4. One patient in Cohort A died of pneumonia (unrelated to treatment), one patient in cohort B withdrew from trial on Day 22 to commence palliative care.
Cynata believes there is broad applicability of its platform across multiple clinical targets.

**Cymerus™ Platform**

*Pre-clinical data available for 7 conditions*

- Graft vs Host Disease (GvHD)
- Heart attack
- Brain cancer / Glioblastoma
- Graft vs Host Disease (GvHD)
- Sepsis
- Asthma
- Critical Limb Ischemia (CLI)
- Fistula
- Pre-clinical data
- Coronary Artery Disease
- Cytokine Release Syndrome
- Diabetic wounds
- Acute respiratory distress syndrome
- Others

**Potential future target areas**

- Coronary Artery Disease
- Cytokine Release Syndrome
- Brain cancer / Glioblastoma
- Diabetic wounds
- Acute respiratory distress syndrome
- Others

**Partnership-Phase II planned**

- Partnership-Phase II planned in 2019

**Pre-clinical data**

- Pre-clinical data available for 7 conditions

**Clinical targets**

- Heart attack
- Brain cancer / Glioblastoma
- Graft vs Host Disease (GvHD)
- Sepsis
- Asthma
- Critical Limb Ischemia (CLI)
- Fistula
- Pre-clinical data
- Coronary Artery Disease
- Cytokine Release Syndrome
- Diabetic wounds
- Acute respiratory distress syndrome
- Others

**Others**

- Others
- Potential future target areas

**Funding**

- Osteoarthritis (funded by NHMRC)
Investment Summary

✓ Next generation **scalable technology**: proprietary Cymerus™ platform capable of producing **commercial quantities of cellular therapy products**

✓ All endpoints achieved in **world-first allogeneic iPSC-derived cell therapy clinical trial** of 15 patients with steroid-resistant acute GvHD
  - ✓ no adverse safety events
  - ✓ highly encouraging efficacy

✓ **Endorsement by Big Pharma** via licence option agreement with FUJIFILM in GvHD

✓ **Value inflection point**: demonstrated success in GvHD clinical trial supports further licence agreements in other indications which have shown attractive pre-clinical results

✓ **Cynata is in active discussions regarding further licence agreements** and strategic partnerships in other indications

✓ **Multiple Phase 2 clinical studies** (GvHD; CLI; osteoarthritis) anticipated to commence over the next 12 months
Thank you for your attention

Cynata Therapeutics Limited
Level 3
62 Lygon Street
Carlton
Victoria 3053
Australia

Contact details:
ross.macdonald@cynata.com
www.cynata.com